Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
Both the steroid- and NSAID-sparing effects of biologics in juvenile idiopathic arthritis (JIA) treatment are key aspects of the dynamics of patient ’s condition. The proper selection of biologics enables maximum treatment effectiveness and reduction of the dosage of concomitant therapy. Our aim was to study the dynamics of concomitant therapy during etanercept (ETA) and methotrexate (MTX) treatment in patients with JIA.
Source: Pediatrics and Neonatology - Category: Perinatology & Neonatology Authors: Ekaterina Alexeeva, Tatyana Dvoryakovskaya, Rina Denisova, Tatyana Sleptsova, Kseniya Isaeva, Alexandra Chomahidze, Anna Fetisova, Anna Mamutova, Alina Alshevskaya, Victor Gladkikh, Andrey Moskalev Tags: Original Article Source Type: research
More News: Arthritis | Children | Enbrel | Methotrexate | Pediatrics | Perinatology & Neonatology | Rheumatology | Study